| Date | Title | Description |
| 09.04.2026 | Amazon Pharmacy Partners with Eli Lilly to Offer Foundayo GLP-1 with Same-Day Delivery | What You Should Know
The Drug: Amazon Pharmacy is now dispensing Foundayo™, Eli Lilly’s recently approved, once-daily oral GLP-1 medication indicated for adults with obesity or overweight with weight-related medical problems.
The Pricing: A... |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 06.04.2026 | Motorola Solutions' Greg Brown Is Chief Executive Magazine's 2026 CEO of the Year | Chief Executive magazine announced Motorola Solutions Chairman and CEO Greg Brown as 2026 Chief Executive of the Year, recognizing his leadership in transforming the company into a leading safety and security technology provider and deliver... |
| 03.04.2026 | Foundayo Arrives: Eli Lilly's Pill Set to Transform Weight Loss | Eli Lilly's Foundayo receives swift FDA approval. This daily oral GLP-1 pill targets obesity, expanding treatment options. Foundayo offers convenience and improved health outcomes, albeit with less weight loss than injectables. Competitive ... |
| 03.04.2026 | GLP-1 Revolution: Novo Nordisk Innovates Pricing, Expands Health Impact | Novo Nordisk aggressively reshapes the GLP-1 landscape. It launches multi-month Wegovy subscriptions in the U.S., ensuring predictable pricing and bolstering patient adherence against Eli Lilly's market dominance. Concurrently, the UK's NIC... |
| 03.04.2026 | Lilly покупает британского разработчика лекарства от расстройства сна за $7,8 млрд | Препарат Zepbound компании Eli Lilly & Co. помогает решать одну из самых сложных проблем здравоохранения нашего времени — ожирение. Теперь фармкомпания берется за еще одну серьезную проблему общественного здоровья: расстройства сна.
В с... |
| 02.04.2026 | AI Investment Surge Fuels Market Rally Amid Geopolitical Hopes | Nvidia poured $2 billion into Marvell Technology. This investment strengthens AI infrastructure. It expands Nvidia's vital AI ecosystem. Marvell shares jumped significantly. The partnership targets custom AI chips, advanced silicon photonic... |
| 02.04.2026 | Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t cheap. Related Articles
Trump has private... |
| 02.04.2026 | Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary | Getting your Trinity Audio player ready...
By WYATTE GRANTHAM-PHILIPS, AP Business Writer
NEW YORK (AP) — President Donald Trump signed an executive order Thursday that could slap long-threatened pharmaceutical tariffs of up to 100% on some... |
| 02.04.2026 | Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison | Oral Wegovy demonstrated “significantly greater mean weight loss” than Lilly’s rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday.
Novo’s findings evaluated previously published studies of the medicines and did no... |
| 02.04.2026 | Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs | The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned.
The Trump administration is... |
| 02.04.2026 | It’s not just vaccines — parents are refusing other routine preventive care for newborns | Getting your Trinity Audio player ready...
By LAURA UNGAR, AP Medical Writer
One day at an Idaho hospital, half the newborns Dr. Tom Patterson saw didn’t get the vitamin K shots that have been given to babies for decades to prevent potentia... |
| 02.04.2026 | Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions | Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions.
The presentati... |
| 02.04.2026 | 5 Things to Know
Trump’s address, SpaceX IPO, Sam’s Club membership prices and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Thursday. It’s the one-year anniversary of President Donald Trump’s initial tariff unveiling, what the president dubbed “liberation day... |
| 01.04.2026 | Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more | - |
| 01.04.2026 | Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people | Novo Nordisk weight loss drug Wegovy was recommended by England’s drug price regulator to prevent heart attacks and strokes.
The new recommendation from NICE will significantly expand access to Wegovy on the country’s National Health Servic... |
| 01.04.2026 | FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity | Getting your Trinity Audio player ready...
By JONEL ALECCIA, AP Health Writer
Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.
Th... |
| 01.04.2026 | FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market | The FDA approved a GLP-1 pill from Eli Lilly called Foundayo.
Foundayo isn’t as effective as Lilly’s weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenience, and it can be scaled around the world... |
| 01.04.2026 | Eli Lilly opposes push to pass Trump’s drug pricing deals into law, CEO says | Eli Lilly opposes the White House’s push to codify ‘most favored nation’ drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC.
Lilly is one of more than a dozen pharmaceutical companies that have signed MFN deals with the Trump... |
| 01.04.2026 | Eli Lilly secures long-awaited FDA approval for its obesity pill. Here’s what to know | - |
| 31.03.2026 | AI Revolutionizes Pharma: Eli Lilly and Insilico Medicine Forge $2.75B Drug Discovery Alliance | Pharma giant Eli Lilly forms a monumental AI drug discovery alliance with Insilico Medicine. Insilico's advanced generative AI platform, Pharma.AI, will accelerate the identification and development of novel therapeutics across diverse dise... |
| 31.03.2026 | Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly | Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, “predictable” monthly prices.
Eligible patients can choose between three-, six- or 12-month su... |
| 31.03.2026 | Stocks soar on hopes of Iran war resolution — plus, Lilly takes a big swing in sleep disorders | - |
| 31.03.2026 | European stocks post worst month since 2022 as Iran war drags on | LONDON — European stocks rose on Tuesday but rounded-off their worst monthly performance in six years, as uncertainty over the trajectory of the Iran war lingers.
The pan-European Stoxx 600 climbed 0.43%, after briefly dipping into negative... |
| 31.03.2026 | Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs | Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals.
Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
The deal is the latest from Lilly, which is using its GLP-1 windfall to place mo... |
| 31.03.2026 | 5 Things to Know
Wall Street’s rough month, Powell’s inflation outlook, GLP-1 subscription and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. In a partnership you might not have seen coming, Warren Buffett is teaming up with the NBA’s Stephen Curry to revive his iconi... |
| 31.03.2026 | Insilico Medicine's Shares Drop After Founder Rebuts Eli Lilly Buyout Rumor | (Yicai) March 31 -- Shares of Insilico Medicine Cayman, a Hong Kong-listed biotechnology firm that uses artificial intelligence to discover and design new drugs, fell after its founder denied speculation of a takeover by US drugmaker Eli Li... |
| 31.03.2026 | The Dow surges more than 1,100 points as Wall Street soars to its best day since last spring | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stocks surged to their best day since last spring, and the Dow Jones Industrial Average soared 1,125 points on Tuesday as doubt swung back to h... |
| 30.03.2026 | 5 Things to Know
Oil’s record month, TSA pay, the Pokémon card resale market and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Monday. This article about the future of film studios’ animated slates was the reminder I needed to go see “Hoppers,” as it feels like ... |
| 30.03.2026 | Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery | March 29 : Insilico Medicine said on Sunday it is partnering with Eli Lilly in a deal worth up to $2.75 billion, expanding an existing collaboration on AI-powered drug discovery.
Lilly will use Insilico's AI engine and receive an exclusive ... |
| 30.03.2026 | Insilico Medicine Announces Global R&D Collaboration with Lilly | AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas.
CAMBRIDGE, Mass., March 30, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinic... |
| 30.03.2026 | Insilico Medicine and Eli Lilly Form $2.75B AI Drug Discovery Collaboration | Insilico Medicine and Eli Lilly Announce $2.75B AI Drug Discovery Collaboration
– Drug Discovery Collaboration: Insilico Medicine, an AI-native clinical-stage biotech, has signed a massive drug discovery collaboration with pharma giant Eli ... |
| 29.03.2026 | Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market | Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs.
The two companies have worked together since 2023.
Insilico’s CEO, Alex Zhavoronkov, said Eli Lilly has a competitive edge in ce... |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 23.03.2026 | Umlaut.bio extends pre-seed round to EUR 3 million |
Umlaut.bio is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules will be developed to inhibit key steps in tRNA modification synthesis, thereby preventi... |
| 23.03.2026 | Nitin Garg: “Enterprise Don’t Trust Black Boxes” – Building Transparent AI Automation at AWS | Share
Share
Share
Share
Email
Senior Product Manager at AWS, Nitin Garg, on solving technical challenges that prevent organizations from scaling AI workflow automation
The AI agents market reached $7.84 billion in 2025 and will expand to $5... |
| 23.03.2026 | U.S. executives, from Apple to Eli Lilly, revamp their push into the world’s second-largest economy at the China Development Forum | Household names were among the more than 30 U.S. corporate executives who joined the China Development Forum in Beijing over the weekend.
Fresh off a recovery in Apple iPhone sales in China, CEO Tim Cook took the stage on Sunday after Chine... |
| 22.03.2026 | Crossbow Therapeutics Fuels T-Cell Engager Pipeline with $77 Million Series B | Crossbow Therapeutics secured $77 million in Series B funding to propel its innovative TCR-mimetic antibody cancer therapies. This substantial capital injection will accelerate the development of critical T-cell engager programs. Funds will... |
| 21.03.2026 | GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up | For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.
About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, accord... |
| 20.03.2026 | 5 Things to Know
The Dow’s losing streak, fertilizer prices, Novo Nordisk’s new Wegovy shot and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Friday. In a tale of two viral hotspots, Polymarket is planning a pop-up bar in Washington, D.C., while a New York City pharmacy is see... |
| 19.03.2026 | Crossbow Therapeutics Raises $77M in Series B Funding | Crossbow Therapeutics, a Cambridge, MA-based biotechnology company developing antibody therapies to treat a broad range of cancers, raised $77M in Series B funding.
The round was led by Taiho Ventures and Arkin Bio Capital, with participati... |
| 19.03.2026 | FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share | The Food and Drug Administration approved a higher dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly.
The high-dose Wegovy helped patients with obesity los... |
| 19.03.2026 | Eli Lilly’s new shot shows solid weight loss in study — plus, a way for Nvidia to perk up | - |
| 19.03.2026 | Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial | Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.
The drug lowered hemoglobin A1C by an average of 1.7% ... |
| 19.03.2026 | FDA approves new higher-dose version of Wegovy shots | Getting your Trinity Audio player ready...
By JONEL ALECCIA, AP Health Writer
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users lose more weight and keep it off. Rel... |
| 18.03.2026 | Crossbow Therapeutics: $77 Million Raised To Advance TCR-Mimetic Antibody Cancer Therapies | Crossbow Therapeutics announced it has raised $77 million in a Series B financing to advance the development of its TCR-mimetic antibody therapies designed to treat a broad range of cancers. The funding round was co-led by Taiho Ventures an... |
| 17.03.2026 | Here are Tuesday’s biggest analyst calls: Nvidia, Tesla, Uber, Lemonade, Eli Lilly, Amazon, Align Technology & more | - |
| 17.03.2026 | Eli Lilly shares slide after a bearish Wall Street analyst call — here’s our view | - |
| 17.03.2026 | Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models | - In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 rec... |
| 17.03.2026 | Stocks making the biggest moves midday: Mosaic, Tencent Music, Delta Air Lines, Uber, Eli Lilly & more | - |
| 17.03.2026 | Stocks making the biggest moves premarket: Nvidia, Delta Air Lines, Eli Lilly & more | - |
| 17.03.2026 | Eli Lilly catches a downgrade as HSBC warns of an overhyped obesity drug market | - |
| 14.03.2026 | Elaia Fuels Europe's Deep Tech Future with €134M Fund | Elaia has closed its €134 million DTS3 fund. This deep tech seed fund targets European B2B startups. It doubles prior deep tech allocations. Elaia partners with top research institutions. The fund invests €1M-€13M in early-stage ventures. F... |
| 13.03.2026 | These stocks will benefit from AI and an aging population, Jefferies says. They also pay dividends | - |
| 12.03.2026 | Elaia closes €134M fund DTS3 to back Europe’s next generation of breakthrough startups | Elaia has closed its third deep tech seed fund (DTS3) at €134 million, double the size of its previous deep tech seed funds. The fund is developed in partnership with leading European research institutions, including PSL, INRIA, CNRS, the B... |
| 12.03.2026 | Abivax denies French media report of AstraZeneca takeover | Abivax shares soared on Thursday after a French media report that AstraZeneca was in talks to acquire it.
But a company spokesperson denied the report to CNBC.
Abivax has been the subject of intense takeover speculation for months.
French b... |
| 12.03.2026 | Elaia closes third DeepTech Seed fund at €134 million as “European DeepTech is reaching escape velocity” | Paris-based VC firm Elaia has announced the closing of its third DeepTech Seed fund (DTS3) at €134 million, which is double the size of its previous DeepTech Seed funds.
DTS3’s final closing includes support from longtime partners and new i... |
| 11.03.2026 | Jim Cramer says Eli Lilly has checked the most important box as obesity pill approval looms | - |
| 10.03.2026 | Mobility Mojo Raises €4.25M in Growth Equity Funding | Mobility Mojo, a Dublin, Ireland-based developer of a workplace accessibility technology platform, raised €4.25m in growth equity funding.
Gresham House Ventures, on behalf of the Gresham House VCTs and Baronsmead VCTs, made the investment.... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 09.03.2026 | Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs | “We have decided to drop the current court proceedings,” Novo CEO Mike Doustdar told CNBC on Monday, however, reserving the right to bring it back “if needed.”
It comes after an agreement between Novo and Hims where Hims will offer access t... |
| 09.03.2026 | GLP-1: Amazon Pharmacy Adds Zepbound KwikPen to Its Same-Day Delivery for $299 | What You Should Know
The Launch: Amazon Pharmacy has officially expanded its weight management portfolio by adding Eli Lilly’s Zepbound® KwikPen® to its digital shelves.
The Hardware: Unlike traditional single-use GLP-1 auto-injectors, the ... |
| 08.03.2026 | Выходец из МГУ привлек $293 млн на ИИ-платформу, которая находит кандидатов в лекарства за месяцы вместо лет | ИИ-платформа Pharma.AI компании Insilico Medicine нашла преклинического кандидата в лекарство за 8 месяцев — при отраслевой норме в 2,5–4 года. Компания, основанная выпускником МГУ Александром Жаворонковым, 30 декабря провела крупнейшее био... |
| 06.03.2026 | AWS Launches Amazon Connect Health for AI-Powered Healthcare Administration | Image generated by AI
Amazon Web Services has launched Amazon Connect Health, a new AI platform designed to automate administrative work for healthcare providers, including patient verification, appointment scheduling, documentation, and me... |
| 06.03.2026 | Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’ | Shares of Danish drugmaker Zealand Pharma fell more than 35% after trial patients lost less weight than expected with its experimental medicine.
CEO Adam Steensberg told CNBC that, in the real world, Zealand’s drug offers massive potential ... |
| 05.03.2026 | Novo Nordisk Fortifies Global Oral GLP-1 Supply with $506M Ireland Expansion | Novo Nordisk is investing €432 million ($506 million) to expand its oral GLP-1 manufacturing in Athlone, Ireland. This massive expansion boosts production capacity for international markets, excluding the U.S. It marks a critical strategic ... |
| 05.03.2026 | Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. | Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients.
The “Employer Connect” platform gives employers more flexibility in how they cover obesity t... |
| 02.03.2026 | Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly | Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland.
The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo executive Kasper Bødker Mejlvang.
It comes... |
| 02.03.2026 | Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 28.02.2026 | Novo Nordisk Faces Setback as Key Weight Loss Drug Falls Short | Novo Nordisk experienced a significant blow. Its experimental weight-loss medication, CagriSema, failed to meet expectations in a crucial clinical trial. The drug did not demonstrate non-inferiority against Eli Lilly's rival product, tirzep... |
| 28.02.2026 | Novo Nordisk Slashes GLP-1 Drug Prices, Reshaping US Healthcare Access | Novo Nordisk announces significant price reductions for its flagship GLP-1 medications, Ozempic, Wegovy, and Rybelsus. List prices will drop by up to 50% starting January 2027. This strategic shift targets insured patients, particularly tho... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 26.02.2026 | Ozempic, Wegovy list prices to be slashed by up to 50% | Getting your Trinity Audio player ready...
Weight loss drugmaker Novo Nordisk will cut the list prices of Ozempic and Wegovy by up to 50% beginning in 2027, the company announced this week.
Wegovy currently carries a list price of $1,349 pe... |
| 26.02.2026 | Dynavox Group bolsters management team to support effective growth and scaling | Dynavox Group bolsters management team to support effective growth and scaling
Thu, Feb 26, 2026 09:00 CET Report this content
Dynavox Group, the world leader in assistive communication, today announced that it has appointed two new members... |
| 25.02.2026 | Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner | - |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 24.02.2026 | 5 Things to Know
Meta-AMD chip deal, Wall Street’s AI angst, Trump’s State of the Union and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. I found yesterday’s snowfall to be quite idyllic, granted I didn’t actually step foot outside until it had stopped (don’t repe... |
| 24.02.2026 | Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients | Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027.
The move aims to make the treatments more accessible to patients with insurance cove... |
| 23.02.2026 | Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial | Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide.
The stock plummeted on Monday, hitting its lowest level since June 2021.
The Danish dru... |
| 23.02.2026 | Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen | Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month’s worth of doses in a single pen.
The pen could serve as a more convenient option for some patients, as it reduces the number of devices ... |
| 23.02.2026 | US stocks drop after Trump ramps up his tariffs and worries flare about potential AI losers | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stocks are falling Monday after President Donald Trump took little time to ramp up his newest tariffs, and as investors continue to punish comp... |
| 23.02.2026 | Novo Nordisk shares tumble after drug trial falls short | Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff.
The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 25... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 23.02.2026 | Eli Lilly’s lead in the obesity race gets wider after another win against rival Novo Nordisk | - |
| 20.02.2026 | Buy this best-in-class GLP-1 leader as competition heats up, says Barclays | - |
| 19.02.2026 | BlackRock сконцентрировала в 2026 году $1,8 трлн в 10 акциях: ставка на Big Tech и AI | Речь идет преимущественно о технологических гигантах США, которые стали бенефициарами бума искусственного интеллекта и роста рынка полупроводников. ТОП-10 крупнейших позиций BlackRock (Q4 2025)
NVIDIA — $363 млрд
Apple — $314 млрд
Microsoft... |
| 19.02.2026 | Американская фармкомпания Johnson & Johnson инвестирует $1 млрд в завод клеточной терапии в США | J&J инвестирует $1 млрд в новый завод в Пенсильвании на фоне курса США на развитие производства. Johnson & Johnson сообщила в среду, что вложит более $1 млрд в строительство нового предприятия по производству клеточной терапии в шта... |
| 19.02.2026 | Hope For The Warriors Awarded $3 Million Grant From Lilly Endowment | Hope For The Warriors has received a $3 million grant from Lilly Endowment Inc. to strengthen its organizational foundation and expand access to evidence-based support for military families nationwide.
The funding is part of a broader initi... |
| 18.02.2026 | Exclusive: NHS must keep medicine clawback down or lose investment, says weight-jab boss | The NHS must keep its medicines clawback tax low and predictable or else risk disrupting the rollout of weight-loss drugs in the UK, Novo Nordisk’s UK chief has said.
Sebnem Avsar Tuna, general manager of UK operations for the Ozempic and W... |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 11.02.2026 | Eli Lilly Secures Future with Orna Therapeutics Acquisition | Eli Lilly acquired Orna Therapeutics. The deal totals up to $2.4 billion. This secures groundbreaking circular RNA technology. Orna pioneers *in vivo* cell engineering. Their platform allows the body to generate therapies internally. This b... |
| 11.02.2026 | Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs | Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments.
Doustdar said he doesn’t expect Medicare access to obesity treatments, expected later this... |
| 10.02.2026 | «Дочка» Alphabet представила ИИ-движок для дизайна лекарств — вдвое точнее AlphaFold 3 | Isomorphic Labs, дочерняя компания Alphabet и сестринская структура Google DeepMind, представила IsoDDE (Isomorphic Labs Drug Design Engine) — единый вычислительный движок для проектирования лекарственных молекул. На самом сложном бенчмарке... |
| 10.02.2026 | CVS tops quarterly estimates, reaffirms profit outlook as turnaround plan takes effect | CVS Health reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that previously impressed investors.
The results signal steady progress in the health-care giant’s aggressive turnaround pla... |
| 09.02.2026 | Eli Lilly and Company to Acquire Orna Therapeutics, For Up To $2.4 Billion | Eli Lilly and Company (NYSE: LLY) is to acquire Orna Therapeutics, Inc., a Waterotown, Mass.-based biotechnology company dedicated to engineering immune cells in vivo.
Under the terms of the agreement, Lilly will acquire Orna, and Orna shar... |
| 09.02.2026 | Фармкомпания Eli Lilly покупает американскую биотех-компанию Orna Therapeutics за $2,4 млрд | Американская фармацевтическая компания Eli Lilly (LLY.N) согласилась купить биотехнологическую компанию Orna Therapeutics за $2,4 млрд наличными, получив доступ к технологии, которая позволяет использовать собственные клетки пациентов для с... |
| 09.02.2026 | Haveli Investments Acquires Budge Studios from General Atlantic | Haveli Investments, an Austin-based private equity firm specializing in technology and gaming, acquired Budge Studios, a Montreal, Canada-based developer of digital interactive entertainment for children, from General Atlantic.
The amount o... |
| 08.02.2026 | AstraZeneca's Historic NYSE Move Reshapes Global Biopharma Landscape | AstraZeneca completed a landmark transfer to the New York Stock Exchange. Its ordinary shares now trade there, a historic move. It represents the largest company transfer by market capitalization in NYSE history. This strategic shift harmon... |
| 08.02.2026 | Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology | SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for ... |
